Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Adults taking Zepbound in a clinical trial lost on average 48 lb. at the highest dose Zepbound is the first and only approved treatment activating two incretin hormone receptors, GIP and GLP-1, to tackle an underlying cause of excess weight INDIANAPOLIS , Nov. 8, 2023 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company's (NYSE: LLY) Zepbound™ (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.

FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems

The obesity approval further establishes Eli Lilly as a formidable competitor to Novo Nordisk in the budding weight loss drug industry.

FDA approves Eli Lilly's tirzepatide for obesity, paving way for even wider use of blockbuster drug

Eli Lilly now forecasts that it will have lower profits this year than previously projected. Usually, announcements of that type take the wind out of a stock's price.

Eli Lilly Slashed Its Earnings Guidance and Its Stock Went Up 5% Anyway. What's Next?

Airbnb

Arista Networks

Carnival

Ceridian HCM Holding Inc.

DexCom

First Solar

Fortinet

General Electric

Las Vegas Sands

Lamb Weston Hlds

Mondelez

Norwegian Cruise Line

ServiceNow

PACCAR

Insulet

Royal Caribbean Cruises

Roper Technologies

Westinghouse Air Brake Technologies

Earnings season is a time when investors like to see a “beat and raise” pattern. That is, companies report sales and earnings that surprise the market by coming in ahead of analysts' estimates.

Earnings-season winners: 20 companies that have grown sales while improving profit margins

Eli Lilly was an S&P 500 top performer Monday, while energy plays were among the day's biggest winners and losers.

Eli Lilly, Power Generators Lead Top S&P 500 Performers Monday

Dr. Daniel Skovronsky believes a big leap in Alzheimer's disease treatment may be just around the corner–and that an overlooked class of medicines could become the GLP-1 drugs of the future.

Eli Lilly chief scientific officer ‘extremely optimistic' that major new Alzheimer's breakthrough is coming

Novo Nordisk

The anti-obesity market could become a $100 billion industry by 2030, Goldman Sachs predicts. The field is "still in its early stages" but may have reached an inflection point, the bank said.

Ozempic and other weight-loss drugs will power the anti-obesity market to 16-fold gains by 2030, Goldman Sachs says

Deckers Outdoor

Shell PLC

Brand power is real. The brand that consumers associate with a company is quantifiable and something valued.

The Importance of Brand Power: 3 Stocks to Consider

iShares U.S. Pharmaceuticals ETF

iShares U.S. Healthcare ETF

Harbor Health Care ETF

Horizon Kinetics Medical ETF

Health Care Select Sector SPDR Fund

Eli Lilly (LLY) posted robust third-quarter 2023 earnings results, beating estimates on both the top and bottom lines. Its Mounjaro anti-obesity drug continued its robust performance.

Eli Lilly Beats on Q3 Earnings: ETFs to Buy

Eli Lilly just earned FDA approval of a treatment for ulcerative colitis. There is already plenty of competition on the market for this condition.

Eli Lilly Just Added Another Potential Billion-Dollar Product: Is It a Buy?

Novo Nordisk delivered sizzling Q3 growth, thanks mainly to soaring sales for Ozempic. However, Eli Lilly's Q3 results looked even better than Novo Nordisk's.

Ozempic Sales Soar 56% in Q3. But Is Eli Lilly a Better Stock to Buy Than Novo Nordisk?

Eli Lilly and Co (LLY) Q3 2023 Earnings Conference Call Transcript

Novo Nordisk and Eli Lilly both expect juggernaut sales for their diabetes and weight-loss drugs to extend into coming years - limited only by their availability.

Novo Nordisk, Lilly see insatiable demand for weight-loss drugs

While the top- and bottom-line numbers for Lilly (LLY) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Compared to Estimates, Lilly (LLY) Q3 Earnings: A Look at Key Metrics

Eli Lilly (LLY) beats third-quarter estimates for earnings as well as sales. It cut its earnings guidance for 2023 on charges related to acquisitions and collaboration deals.

Eli Lilly (LLY) Q3 Earnings & Sales Top, EPS View Cut, Stock Up

The remarks suggest that Eli Lilly's initial efforts to expand manufacturing capacity for Mounjaro are paying off as demand for the diabetes treatment soars.

Eli Lilly says supply of blockbuster diabetes drug Mounjaro has improved in U.S.

Eli Lilly, which makes Mounjaro, and Denmark's Novo Nordisk, which makes Ozempic and Wegovy, are struggling to meet skyrocketing demand for their medications.

Obesity Drug Demand Outstrips Supply

Eli Lilly and Co (NYSE:LLY) reported impressive third-quarter revenue as its diabetes drug Mounjaro exceeded sales expectations. The blockbuster drug generated quarterly sales of $1.41 billion, marking a 44% increase from the previous quarter and surpassing analysts' estimates of $1.26 billion.

Eli Lilly sees strong 3Q sales fueled by Mounjaro but cuts profit outlook

INDIANAPOLIS , Nov. 2, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of pirtobrutinib, a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 9-12 in San Diego. The presentations will provide updated, longer follow-up clinical safety and efficacy data for approved and investigational uses of pirtobrutinib from the ongoing Phase 1/2 BRUIN study in multiple B-cell malignancies.

Lilly Announces Details of Pirtobrutinib Presentations in B-Cell Malignancies at 2023 ASH Annual Meeting

Lilly slashes its guidance for full-year earnings to a range of $6.50 to $6.70 a share, having raised its outlook in August to a range of $9.70 to $9.90.

Eli Lilly Stock Falls as Earnings Guidance Slashed Dramatically

Shares of Eli Lilly & Co. LLY, +0.10% dropped 1.8% in premarket trading Thursday, after the drug giant reported a surprise third-quarter profit but slashed its full-year outlook, due primarily to acquired in-process research and development charges. The company swung to a net loss of $57.4 million, or 6 cents a share, from net income of $1.45 billion, or $1.61 a share, in the year-ago period.

Eli Lilly's stock drops after surprise profit is reported but full-year outlook was slashed

Comcast

Li Auto Inc.

NVIDIA

Symbotic Inc

Last year wasn't the best year for tech stocks. Some of the biggest names on Wall Street stumbled through the year as companies that were flush with growth during the Covid-19 pandemic adjusted to leaner times.

7 A-Rated Tech Stocks to Buy for November

Eli Lilly beat Wall Street's revenue estimates for the third quarter on Thursday, lifted by strong demand for its diabetes drug Mounjaro that brought in over a billion dollars in sales.

Eli Lilly beats quarterly revenue estimates on Mounjaro strength

Revenue in Q3 2023 increased 37%, driven by growth from Mounjaro, Verzenio and Jardiance, as well as $1.42 billion from the sale of rights for the olanzapine portfolio (Zyprexa). Excluding revenue from the olanzapine portfolio and COVID-19 antibodies, revenue in Q3 2023 increased 24%.

Lilly Reports Third-Quarter 2023 Financial Results, Highlights Strong Sales Growth and Business Development Activity

Evaluate the expected performance of Lilly (LLY) for the quarter ended September 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

News for Eli Lilly Stock (LLY)